News Wire

Treatment with SAGE-217 (Sage Therapeutics) led to significant improvements on a depression rating scale and remission among 64% of patients with major depressive disorder (MDD) at day 15, according to phase 2 data released by the company.  “If successfully developed, SAGE-217 has the potential to…
About 15 million Americans will have either Alzheimer's dementia or mild cognitive impairment by 2060, up from approximately 6.08 million this year, according to a new study by researchers at the UCLA Fielding School of Public Health. The findings highlight the need to develop measures that could slow…
The FDA has approved semaglutide injection 0.5 mg or 1 mg (Ozempic, Novo Nordisk), a once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes. The medication is administered once weekly, on the…
And the lines, they are a blurring. Just days after CVS Health announced that it wants to buy Aetna for $69 billion, another megadeal looks to further integrate different functions in the health care system. Optum’s proposed purchase of DaVita Medical Group means that the nation’s largest insurer…
The proposed purchase of Aetna Inc. by CVS Health Corp. will change the way many major U.S. corporations buy health coverage for employees and raise new questions over the cost of those benefits, benefit consultants said. CVS said Sunday it planned to buy Aetna for $69 billion, according to a Reuters…
The FDA has approved ixekizumab injection 80 mg/mL (Taltz, Eli Lilly and Company) for the treatment of adults with active psoriatic arthritis (PsA). Ixekizumab was first approved by the FDA in March 2016 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic…
Evolocumab (Repatha, Amgen) has become the first PCSK9 inhibitor approved by the FDA to prevent heart attacks, strokes, and coronary revascularizations in adults with established cardiovascular disease. The FDA also approved evolocumab to be used as an adjunct to diet, alone or in combination with other…
In what’s being described as a landmark deal in the health care industry, CVS Health has agreed to buy Aetna for $69 billion, the Wall Street Journal (WSJ) reports. Unlike the proposed deals that would have allowed the mergers of Cigna and Anthem, and Aetna and Humana—which the courts barred this…
The FDA has approved trastuzumab-dkst (Ogivri, Mylan) as a biosimilar to trastuzumab (Herceptin, Genentech) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Ogivri is the first…
The FDA has approved Sublocade (Indivior Inc.), the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder (OUD) in adult patients who have initiated treatment with a transmucosal buprenorphine-containing product. It is indicated for patients…
They’re this close, the Wall Street Journal reports. And if CVS Health is able to buy Aetna for a reported $66 billion in cash and stock, it will roil the health care industry, creating a colossus that will sell everything from drugs to insurance. It would be the biggest merger of the year and the…
Fremanezumab (Teva Pharmaceuticals), an immunotherapy that counteracts a molecule released during migraine, reduced the number of days that chronic migraine sufferers experienced headaches in phase 3 trial results published by the New England Journal of Medicine. The World Health Organization estimates…
Researchers have announced the launch of two large studies in Africa to test a new vaccine for the human immunodeficiency virus (HIV) and a long-acting injectable drug, fuelling hopes for better ways to protect against the virus. Reuters reports that the start of the three-year vaccine trial involving…
The FDA is aiming to approve drugs based on very early data if the medication shows a possible benefit in terms of survival, the head of the agency told lawmakers at a House committee hearing. Speaking before the House Committee on Energy and Commerce, FDA Commissioner Scott Gottlieb, MD, said the agency…
Diabetes costs employers about $20 billion a year thanks to about 57 million unplanned sick days for workers, according to a report by Gallop and Sharecare, a health and wellness engagement company. The prevalence of diabetes in the adult population grew, from 10.6% in 2008 to 11.6% in 2016. It was…

Pages

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to jfedder1@hfhs.org or online at http://p.rfer.us/HENRYFORDlXqAJA